Medicinal composition usable for preventing and/or treating blood coagulation factor IX abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor VIII

Patent Citations (497)

Non-Patent Literature (643)

• Bolton-Maggs, Paula HB, and K. John Pasi. The Lancet 361.9371 (2003): 1801-1809 (Year: 2003).Examiner
• Rallapalli, P M et al. Journal of thrombosis and haemostasis :JTH vol. 11,7 (2013): 1329-40. doi: 10.1111/jth. 12276 (Year: 2013).Examiner
• Kitazawa, Takehisa et al. Thrombosis and haemostasis vol. 117,7 (2017): 1348-1357. doi: 10.1160/TH17-01-0030 (Year: 2017).Examiner
• Janeway, Charles A. “Immunobiology: The Immune System in Health and Disease.” 2001 (Year: 2001).Examiner
• Uchida, Naoki, et al. “A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.” Blood, The Journal of the American Society of Hematology 127.13 (2016): 1633-1641 (Year: 2016).Examiner
• Alshaikhli A, Killeen RB, Rokkam VR. Hemophilia B. [Updated Oct. 29, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2025. (Year: 2023).Examiner
• Rountree KM, Yaker Z, Lopez PP. Partial Thromboplastin Time. [Updated Aug. 14, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2025 (Year: 2023).Examiner
• Lee, Kyumin, et al. “Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.” Blood 144.11 (2024): 1230-1235 (Year: 2024).Examiner
• U.S. Appl. No. 14/351,654, filed Apr. 14, 2014, Kuramochi et al.Applicant
• U.S. Appl. No. 14/921,590, filed Oct. 23, 2015, Hattori et al.Applicant
• U.S. Appl. No. 15/172,727, filed Jun. 3, 2016, Hattori et al.Applicant
• U.S. Appl. No. 16/008,486, filed Jun. 14, 2018, Igawa et al.Applicant
• U.S. Appl. No. 16/061,429, filed Jun. 12, 2018, Igawa et al.Applicant
• U.S. Appl. No. 16/093,495, filed Oct. 12, 2018, Saeki et al.Applicant
• U.S. Appl. No. 16/099,341, filed Nov. 6, 2018, Teranishi et al.Applicant
• U.S. Appl. No. 16/330,269, filed Mar. 4, 2019, Yoneyama et al.Applicant
• U.S. Appl. No. 16/692,676, filed Nov. 22, 2019, Kuramochi et al.Applicant
• U.S. Appl. No. 16/758,128, filed Apr. 22, 2020, Hosoguchi et al.Applicant
• U.S. Appl. No. 16/780,977, filed Feb. 4, 2020, Yoneyama.Applicant
• U.S. Appl. No. 16/815,089, filed Mar. 11, 2020, Igawa et al.Applicant
• U.S. Appl. No. 16/825,513, filed Mar. 20, 2020, Hattori et al.Applicant
• U.S. Appl. No. 16/936,575, filed Jul. 23, 2020, Teranishi et al.Applicant
• U.S. Appl. No. 17/017,971, filed Sep. 11, 2020, Yoneyama.Applicant
• U.S. Appl. No. 17/076,938, filed Oct. 22, 2020, Igawa et al.Applicant
• U.S. Appl. No. 17/130,736, filed Dec. 22, 2020, Hattori et al.Applicant
• U.S. Appl. No. 17/235,445, filed Apr. 20, 2021, Yoneyama.Applicant
• U.S. Appl. No. 17/336,538, filed Jun. 2, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/359,867, filed Jun. 28, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/389,534, filed Jul. 30, 2021, Hattori et al.Applicant
• U.S. Appl. No. 17/483,898, filed Sep. 24, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/485,818, filed Sep. 27, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/520,368, filed Nov. 5, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/528,371, filed Nov. 17, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/534,566, filed Nov. 24, 2021, Yoneyama.Applicant
• U.S. Appl. No. 17/563,149, filed Dec. 28, 2021, Igawa et al.Applicant
• U.S. Appl. No. 17/574,614, filed Jan. 13, 2022, Igawa et al.Applicant
• U.S. Appl. No. 17/578,524, filed Jan. 19, 2022, Igawa et al.Applicant
• U.S. Appl. No. 17/699,293, filed Mar. 21, 2022, Hattori et al.Applicant
• U.S. Appl. No. 17/763,948, filed Mar. 25, 2022, Yoneyama et al.Applicant
• U.S. Appl. No. 17/729,471, filed Apr. 26, 2022, Igawa et al.Applicant
• U.S. Appl. No. 17/828,752, filed May 31, 2022, Yoneyama et al.Applicant
• U.S. Appl. No. 17/849,879, filed Jun. 27, 2022, Yoneyama.Applicant
• U.S. Appl. No. 17/821,494, filed Aug. 23, 2022, Igawa et al.Applicant
• U.S. Appl. No. 17/974,914, filed Oct. 27, 2022, Hattori et al.Applicant
• U.S. Appl. No. 18/081,874, filed Dec. 15, 2022, Igawa et al.Applicant
• U.S. Appl. No. 18/156,559, filed Jan. 19, 2023, Yoneyama et al.Applicant
• U.S. Appl. No. 18/164,709, filed Feb. 6, 2023, Yoneyama.Applicant
• Abe et al., “Novel Protein A Resin: Synthetic Polymer Matrix Design Impact on Antibody Binding Capacity,” JSR Technical Review, 2012, No. 119, pp. 1-5 (with English translation).Applicant
• Abe et al., “Purification of monoclonal antibodies with light-chain heterogeneity produced by mouse hybridomas raised with NS-1 myelomas: application of hydrophobic interaction high-performance liquid chromatography,” J Biochem Biophys Methods, 1993, 27:215-227.Applicant
• Adams et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunol Immunother, 2006, 55:717-727 (2006).Applicant
• Adlersberg et al., “The Immunoglobulin Hinge (Interdomain) Region,” Ric Clin Lab, Jul.-Sep. 1976, 6(3):191-205.Applicant
• Al-Banaa et al., “Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report,” Am J Case Rep, Jul. 18, 2019, 20:1046-1048.Applicant
• Algonomics—Tripole® applications, Feb. 21, 2009, retrieved from the Internet on Feb. 29, 2012 at http://web.archive.org/web20090221052902/http://www.algonomics.com/proteinengineering/tripole_applications.php, 2 pages.Applicant
• Allard et al., “Antigen binding properties of highly purified bispecific antibodies,” Mol Immunol, Oct. 1992, 29(10):1219-1227.Applicant
• Almagro et al., “Humanization of antibodies,” Front Biosci, 2008, 13:1619-1633.Applicant
• Alprolix® Intravenous, 2019, 16 pages (with English translation).Applicant
• Amersdorfer et al., GenPept Accession No. AAC26541, Aug. 2001, 1 page.Applicant
• Amersham Biosciences, “Protein Purification Handbook,” Edition AC, 2001, 98 pages.Applicant
• Annex from opponent 2's submission of Jun. 7, 2018, 13 pages (re-cited by an opponent during the EPO opposition proceedings of EP 2 202 245 on May 19, 2020).Applicant
• Antibodies in Example 29 of EP 2 202 245, 2 pages (cited by the opponent during the EPO opposition proceedings of EP 2 202 245 on May 19, 2020).Applicant
• Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur J Immunol, 1999, 29(8):2613-2624.Applicant
• Arndt et al., “Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment,” Biochemistry, Sep. 15, 1998;37(37):12918-26.Applicant
• Arndt et al., “Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain,” J Mol Biol, 2001, 312:221-228.Applicant
• Aslan et al., “Engineering a novel, stable dimeric streptavidin with lower isoelectric point,” J Biotechnol, 2007, 128(2):213-225.Applicant
• Asselta et al., “Factor V Deficiency,” Semin Thromb Hemost, 2009, 35:382-389.Applicant
• Astermark et al., “A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study,” Blood, Jan. 15, 2007, 109(2):546-51. Epub Sep. 21, 2006.Applicant
• Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” J Mol Biol, 1997, 270:26-35.Applicant
• Baerga-Ortiz et al., “Two different proteins that compete for binding to thrombin have opposite kinetic and thermodynamic profiles,” Protein Sci, 2004, 13(1):166-176.Applicant
• Bajaj et al., “A Monoclonal Antibody to Factor IX That Inhibits the Factor VIII:Ca Potentiation of Factor X Activation,” J Biol Chem, 1985, 260(21):11574-11580.Applicant
• Baker et al., “Immunogenicity of protein therapeutics: The key causes, consequences and challenges,” Self Nonself, Oct. 2010, 1(4):314-322.Applicant
• Barrabes et al., “Effect of sialic acid content on glycoprotein p/ analyzed by two-dimensional electrophoresis,” Electrophoresis, Sep. 2010, 31(17):2903-2912. doi: 10.1002/elps.200900764.Applicant
• Bartelds et al., “Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis,” Ann Rheum Dis, 2007, 66:921-926.Applicant
• Batra et al., “Pharmacokinetics and biodistribution of genetically engineered antibodies,” Curr Opin Biotechnol, Dec. 2002, 13(6):603-608.Applicant
• Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker,” Biotechnology (NY), 1992, 10:169-175.Applicant
• Bender et al., “Immunogenicity, efficacy and adverse events of adalimumab in RA patients,” Rheumatol Int, 2007, 27:269-274.Applicant
• Bessos et al., “The characterization of a panel of monoclonal antibodies to human coagulation factor IX,” Thrombosis Research, 1985, 40:863-867.Applicant
• Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nat Biotechnol, 2005, 23:1257-1268.Applicant
• Blazar, “Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality in Part Via Direct Effects on CD4+ and CD8+ T Cells,” J Immunol, 1996, 157:3250-3259.Applicant
• Bolton-Maggs et al., “Haemophilias A and B,” The Lancet, 2003, 361:1801-1809.Applicant
• Borrebaeck et al., “Antibody evolution beyond Nature,” Nat Biotechnol, Dec. 2002, 20(12):1189-1190.Applicant
• Bos et al., “Enhanced Transfection of a Bacterial Plasmid into Hybridoma Cells by Electroporation: Application for the Selection of Hybrid Hybridoma (Quadroma) Cell Lines,” Hybridoma, 1992, 11:41-51.Applicant
• Bowen, Haemophilia A and haemophilia B: molecular insights, Mol Pathol, Feb. 2002, 55(1):1-18.Applicant
• Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, Mar. 16, 1990, 247:1306-1310.Applicant
• Branden et al., “Recognition of Foreign Molecules by the Immune System,” Introduction to Protein Structure, 2nd ed, Garland Publishing, 1999, pp. 299-323.Applicant
• Brandstetter et al., “X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B,” Proc Natl Acad Sci USA, Oct. 10, 1995, 92(21):9796-9800.Applicant
• Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science, 1985, 229(4708):81-83.Applicant
• Brinkman et al., “Phospholipid-binding domain of factor VIII is involved in endothelial cell-mediated activation of factor X by factor IXa,” Arterioscler Thromb Vasc Biol, 2002, 22(3):511-516.Applicant
• Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” J Immunol, 1996, 156(9):3285-3291.Applicant
• Burges et al., “Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study,” Clin Cancer Res, 2007, 13(13):3899-3905.Applicant
• Burgess, “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,” J Cell Biol, 1990, 111:2129-2138.Applicant
• Cardoso et al., “Neutralizing Human Anti Crotoxin scFv Isolated from a Nonimmunized Phage Library,” Scand J Immunol, Apr. 2000, 51(4):337-344.Applicant
• Carter, “Bispecific human IgG by design,” J Immunol Methods, Feb. 1, 2001, 248(1-2):7-15.Applicant
• Chamow et al., “A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells,” J Immunol, 1994, 153(9):4268-4280.Applicant
• Chatellier et al., “Functional mapping of conserved residues located at the VL and VH domain interface of a Fab,” J Mol Biol, Nov. 22, 1996, 264(1):1-6.Applicant
• Chau et al., “HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor,” Transplantation, 2001, 71(7):941-950.Applicant
• Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J Mol Biol, Nov. 1999, 293(4):865-881.Applicant
• Chen et al., “Defective secretion of an immunoglobulin caused by mutations in the heavy chain complementarity determining region 2,” J Exp Med, 1994, 180(2):577-586.Applicant
• Chen et al., “Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen,” J Exp Med, 1992, 176(3):855-866.Applicant
• Chirino et al., “Minimizing the immunogenicity of protein therapeutics,” Drug Discov Today, 2004, 9:82-90.Applicant
• Choi et al., “Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation,” Mol Immunol, Jun. 2015, 65(2):377-383. doi: 10.1016/j.molimm.2015.02.017. Epub Mar. 2, 2015.Applicant
• Choi et al., “Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening,” PLoS One, Dec. 16, 2015, 10(12):e0145349, 20 pages. doi: 10.1371/journal.pone.0145349. eCollection 2015.Applicant
• Chu et al., “Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures,” Pharm Res, 2007, 24(6):1145-1156.Applicant
• Chugai Seiyaku Kabushiki Kaisha's letter dated Jun. 12, 2013, regarding oral proceedings scheduled on Jun. 26, 2013, in App. Ser. No. EP 06 73 0769.4-1412 (Annex A submitted with patentee's letter dated Jun. 12, 2013).Applicant
• Cole et al., “Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells,” J Immunol, 1997, 159(7):3613-3621.Applicant
• Coloma et al., “Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-→6) dextran antibody,” J Immunol, Feb. 15, 1999, 162(4):2162-2170.Applicant
• Collins et al., “Implications of coagulation factor VIII and IX pharmaco-kinetics in the prophylactic treatment of haemophilia,” Haemophilia, Jan. 2011, 17(1):2-10. doi: 10.1111/j.1365-2516.2010.02370.x. Epub Aug. 22, 2010.Applicant
• Comper et al., “Charge selectivity in kidney ultrafiltration,” Kidney Int, 1995, 47:1242-1251.Applicant
• Coppola et al., “Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A,” Semin Thromb Hemost, Jul. 2012, 38(5):433-446. doi: 10.1055/s-0032-1315757. Epub Jun. 27, 2012.Applicant
• Cordoba et al., “Non-enzymatic hinge region fragmentation of antibodies in solution,” J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 818(2):115-121.Applicant
• Couto et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,” Cancer Res, 1995, 55:1717-1722.Applicant
• Cruse et al., Chapter 3 “Antigens and Immunogens,” Atlas of Immunology, CRC Press LLC, 2004, p. 109.Applicant
• Dahlback, “Blood coagulation,” Lancet, 2000, 355(9215):1627-1632.Applicant
• Dall'Acqua et al., “Antibody humanization by framework shuffling,” Methods, 2005, 36(1):43-60.Applicant
• Dall'Acqua et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” J Biol Chem, Aug. 18, 2006, 281(33):23514-23524. Epub Jun. 21, 2006.Applicant
• Dall'Acqua et al., “Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers,” Biochemistry, Jun. 30, 1998, 37(26):9266-9273. doi: 10.1021/bi980270i. PMID: 9649307.Applicant
• Damschroder et al., “Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties,” Mol Immunol, 2007, 44(11):3049-3060.Applicant
• Dane et al., “Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention,” Res Pract Thromb Haemost, Apr. 9, 2019, 3(3):420-423.Applicant
• Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Adv Drug Deliv Rev, Aug. 7, 2006, 58(5-6):686-706. Epub May 22, 2006.Applicant
• Davie, “A Brief Historical Review of the Waterfall/Cascade of Blood Coagulation,” J Biol Chem, Dec. 19, 2003, 278(51):50819-50832. Epub Oct. 21, 2003.Applicant
• Davie et al., “The coagulation cascade: Initiation, maintenance, and regulation,” Biochemistry, 1991, 30(43):10363-10370.Applicant
• Davies et al., “Antibody VH domains as small recognition units,” Biotechnology (NY), May 1995, 13(5):475-479.Applicant
• De Groot et al., “De-immunization of therapeutic proteins by T-cell epitope modification,” Dev Biol (Basel), 2005, 122:171-194.Applicant
• De Pascalis et al., “Grafting of ‘abbreviated’ complementary-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,” Journal of Immunology, Sep. 15, 2002, 169(6):3076-3084.Applicant
• Decision of the Opposition Division for EP 2 006 381, dated Jul. 25, 2018 (document cited in Ground of Appeal filed on Dec. 4, 2018 by the proprietor, Chugai Seiyaku Kabushiki Kaisha, in connection with the formal appeal lodged on Sep. 19, 2018), 17 pages.Applicant
• Decision of the Opposition Division in EP 2 275 443, dated Apr. 26, 2018 (submitted on May 24, 2019 by the Patentee during EPO opposition proceedings of EP 2 202 245), 29 pages.Applicant
• Declaration of Christian Beil, signed Jun. 18, 2020, 6 pages (submitted by the opponent in EPO opposition proceedings of EP 3 050 963).Applicant
• Declaration of Taichi Kuramochi, signed May 23, 2019, 11 pages (submitted by the Patentee during EPO opposition proceedings of EP 2 202 245 on May 24, 2019).Applicant
• Declaration of Dr. Anette Henriksen, signed Apr. 17, 2019, 4 pages (submitted by the Opponent during EPO opposition proceedings of EP 2 006 381).Applicant
• Deen et al., “Structural determinants of glomerular permeability,” Am J Physiol Renal Physiol, 2001, 281:F579-F596.Applicant
• Del Rio et al., “An Engineered Penicillin Acylase with Altered Surface Charge Is More Stable in Alkaline pH,” Ann NY Acad Sci, 1996, 799:61-64.Applicant
• Deng et al., “An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis,” Blood, 1998, 92:1981-1988.Applicant
• Diaz et al., “Effects of engineering charged amino acids in the CH3 domains on antibody heavy chain dimerization,” Philippine Science Letters, 2011, 4(1):48-55.Applicant
• Do et al., “A rapid method for determining dynamic binding capacity of resins for the purification of proteins,” Protein Expr Purif, Aug. 2008, 60(2):147-150. doi: 10.1016/j.pep.2008.04.009. Epub May 3, 2008.Applicant
• Dumont et al., “Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics,” BioDrugs, 2006, 20(3):151-160.Applicant
• Edelman et al., “The Covalent Structure of an Entire γG Immunoglobulin Molecule,” Proc Natl Acad Sci USA, May 1969, 63(1):78-85.Applicant
• Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J Mol Biol, Nov. 14, 2003, 334(1):103-118.Applicant
• EPO Register Extract EP 1 915 397, 4 pages (document submitted in EPO opposition proceedings and posted by EPO on Feb. 2, 2018).Applicant
• Ewert et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,” Methods, Oct. 2004, 34:184-199.Applicant
• Fay et al., Chapter 2B “Nonenzymatic cofactors: factor VIII,” Comprehensive Biochemistry, 1986, 13:35-37.Applicant
• Fay et al., “The size of human factor VIII heterodimers and the effects produced by thrombin,” Biochim Biophys Acta, 1986, 871(3):268-278.Applicant
• Fay, “Activation of factor VIII and mechanisms of cofactor action,” Blood Rev, Mar. 2004, 18(1):1-15.Applicant
• “FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug,” BioPharm International, Apr. 19, 2018, 1 page, retrieved from the Internet at http://www.biopharminternational.conn/fda-grants-roche-breakthrough-therapy-designation-hemophilia-drug.Applicant
• Feige et al., “How antibodies fold,” Trends Biochem Sci, Apr. 2010, 35(4):189-198. doi: 10.1016/j.tibs.2009.11.005. Epub Dec. 21, 2009.Applicant
• Figini et al., “In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation,” J Mol Biol, May 27, 1994, 239(1):68-78.Applicant
• Franchini et al., “Acquired haemophilia A: A 2013 update,” Thromb Haemost, Dec. 2013, 110(6):1114-1120. doi:10.1160/TH13-05-0363. Epub Sep. 5, 2013.Applicant
• Francois et al., “Construction of a Bispecific Antibody Reacting with the α- and β-Chains of the Human IL-2 Receptor,” J Immunol, 1993, 150:4610-4619.Applicant
• Fujii, “Antibody affinity maturation by random mutagenesis,” Methods Mol Biol, 2004, 248:345-359.Applicant
• “GE Healthcare Life Sciences, Dynamic binding capacity study on MabSelect SuRe™ LX for capturing high-titer monoclonal antibodies,” Application Note 28-9875-25-AA, 2011, 6 pages, retrieved on Feb. 17, 2017 from the Internet at http://www.processdevelopmentforum.com/images/articles/28-9875-25_AA_AN_DBC_study_on_MabSelect_SuRe_LX_final.pdf.Applicant
• Gatiyatov et al., “Antiself Antibodies Against Blood Coagulation Factors,” Siberian Medical Journal, Jun. 2011, 103(4):34-38 (with English translation).Applicant
• Gelderman et al., “The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies,” Lab Invest, 2002, 82(4):483-493.Applicant
• Gerstner et al., “Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody,” J Mol Biol, 2002, 321(5):851-862.Applicant
• Gessner et al., “The IgG Fc receptor family,” Ann Hematol, 1998, 76:231-248.Applicant
• Ghetie et al., “FcRn: the MHC class I-related receptor that is more than an IgG transporter,” Immunol Today, Dec. 1997, 18:592-598.Applicant
• Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nat Biotechnol, Jul. 1997, 15:637-640.Applicant
• Ghetie et al., “Multiple roles for the major histocompatibility complex class I-related receptor FcRn,” Annu Rev Immunol, 2000, 18:739-766.Applicant
• Glatter et al., “Evaluation of Small-Angle Scattering Data from Lamellar and Cylindrical Particles by the Indirect Transformation Method,” J Appl Cryst, 1980, 13:577-584.Applicant
• Gobburu et al., “Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys,” J Pharmacol Exp Ther, 1998, 286:925-930.Applicant
• Goel et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” J Immunol, Dec. 15, 2004, 173(12):7358-7367.Applicant
• Golay et al., “Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays,” Archives of Biochemistry and Biophysics, 2012, 526:146-153.Applicant
• Golay et al., “Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies,” J Immunol, Apr. 1, 2016, 196 (7):3199-3211.Applicant
• Gonzales et al., “Minimizing the immunogenicity of antibodies for clinical application,” Tumour Biol, Jan.-Feb. 2005, 26(1):31-43.Applicant
• Goode et al., “The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?,” Nephrol Dial Transplant, 1996, 11:1714-1716 (1996).Applicant
• Goulet et al., “Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies,” J Biol Chem, Jan. 12, 2018, 293(2):651-661. doi:10.1074/jbc.RA117.000303. Epub Nov. 17, 2017.Applicant
• Gramer et al., “Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches,” mAbs, Nov.-Dec. 2013, 5(6):962-973. doi: 10.4161/mabs.26233. Epub Aug. 22, 2013.Applicant
• Granted claims of EP 2 275 443, 1 page (submitted by the Patentee during EPO opposition proceedings of EP 2 202 245 on May 24, 2019).Applicant
• Grapentin et al., “Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188,” J Pharm Sci, Aug. 2020, 109(8):2393-2404.Applicant
• Graves et al., “Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody,” Clin Cancer Res, Apr. 1999, 5:899-908.Applicant
• Griffin et al., “Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species,” J Immunol Methods, Mar. 2014, 405:35-46. doi: 10.1016/j.jim.2014.01.003. Epub Jan. 18, 2014.Applicant
• Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries,” EMBO J, Feb. 1993, 12(2):725-734.Applicant
• Grosse-Hovest et al., “A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing,” European Journal of Immunology, 2003, 33(5):1334-1340.Applicant
• Guidelines for the management of hemophilia, World Federation of Hemophilia, 2005, 52 pages.Applicant
• Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” J Biol Chem, 2010, 285(25):19637-19646.Applicant
• Gupta et al., “Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates,” J Biochem Biophys Methods, 2002, 51:203-216.Applicant
• Guyre et al., “Increased potency of Fc-receptor-targeted antigens,” Cancer Immunol Immunother, 1997, 45(3-4):146-148.Applicant
• Haagen et al., “Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic,” Cancer Immunol Immunother, Dec. 1994, 39(6):391-396.Applicant
• Hagiwara et al., “Effect of Emicizumab in improving coagulation ability in the presence of minor amount of Factor IX,” Japanese Journal of Thrombosis and Hemostasis, 2017, 28(2):190, 0-012, 2 pages (with English translation).Applicant
• Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, Jun. 3, 1993, 363(6428):446-448.Applicant
• Hämmerling et al., “Use of Hybrid Antibody with Anti-γG and Anti-Ferritin Specificities in Locating Cell Surface Antigens by Electron Microscopy,” J Exp Med, 1968, 128:1461-1473.Applicant
• Hardisty et al., “A One-stage Factor VIII (Antihaemophilic Globulin) Assay and its Use on Venous and Capillary Plasma,” Thromb Diath Haemorrh, May 15, 1962, 7:215-228.Applicant
• Hattori, “Introduction of ART-Ig and application to hemophilia A treatment,” Chugai Pharmaceutical Co., Ltd., Dec. 2012, 18:42-57 (with English translation).Applicant
• He et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin,” J Immunol, 1998, 160:1029-1035.Applicant
• Helfrich et al., “A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions,” J Immunol Methods, 2000, 237(1-2):131-145.Applicant
• Helguera et al., “Antibody-Cytokine Fusion Proteins for the Therapy of Cancer,” Methods Mol Med, 2005, 109:347-374. doi: 10.1385/1-59259-862-5:347. PMID: 15585931.Applicant
• Hemlibra® (emicizumab-kxwh) Prescribing Information, U.S. Food and Drug Administration, Nov. 2017, 16 pages.Applicant
• “Hemophilia and Von Willebrand's disease: 2. Management Association of Hemophilia Clinic Directors of Canada,” Association of Hemophilia Clinic Directors of Canada, Canadian Medical Association Journal, 1995, 153(2):147-157.Applicant
• “Hemostatic Treatment Guidelines for Inhibitor-negative Hemophilia Patients,” Japanese Journal of Thrombosis and Hemostasis, 2013, 24(6):619-639 (with English translation).Applicant
• “Hemostatic Treatment Guidelines for Inhibitor-positive Hemophilia Patients,” Japanese Journal of Thrombosis and Hemostasis, 2013, 24(6):640-658 (with English translation).Applicant
• Hinton et al., “An engineered human IgG1 antibody with longer serum half-life,” J Immunol, Jan. 1, 2006, 176:346-356.Applicant
• Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” J Biol Chem, 2004, 279(8):6213-6216.Applicant
• Hird et al., “Tumour localisation with a radioactively labelled reshaped human monoclonal antibody,” Br J Cancer, Nov. 1991, 64(5):911-914.Applicant
• Ho et al., “In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin,” J Biol Chem, Jan. 7, 2005, 280(1):607-617. doi: 10.1074/jbc.M409783200. Epub Oct. 18, 2004.Applicant
• Hoad et al. “Characterization of monoclonal antibodies to human factor X.Xa: Initial observations with a quantitative ELISA procedure,” J Immunol Methods, 1991, 136(2):269-278.Applicant
• Holliger et al., “‘Diabodies:’ Small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci USA, 1993, 90:6444-6448.Applicant
• Hombach et al., “A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo,” Int J Cancer, 1993, 55:830-836.Applicant
• Hong et al., “Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization,” J Drug Target, 2000, 8(2):67-77.Applicant
• Hotzel et al., “A strategy for risk mitigation of antibodies with fast clearance,” mAbs, Nov.-Dec. 2012, 4(6):753-760. doi: 10.4161/mabs.22189.Applicant
• Hoyer, “The factor VIII complex: structure and function,” Blood, Jul. 1981, 58(1):1-13.Applicant
• Hozumi et al., “Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions,” Proc Natl Acad Sci USA, Oct. 1976, 73(10):3628-3632.Applicant
• Hsia et al., “Treatment of acquired factor X inhibitor by plasma exchange with concomitant intravenous immunoglobulin and corticosteroids,” Am J Hematol, 2008, 83:318-320.Applicant
• Hu et al., “Development and characterization of a novel fusion protein composed of a human IgG1 heavy chain constant region and a single-chain fragment variable antibody against Venezuelan equine encephalitis virus,” J Biochem, 2003, 133(1):59-66.Applicant
• Hugo et al., “Functional aspects of co-variant surface charges in an antibody fragment,” Protein Sci, Nov. 2002, 11(11):2697-2705. doi: 10.1110/ps.0209302. PMID: 12381851; PMCID: PMC2373727.Applicant
• Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Science, 1989, 246:1275-1281.Applicant
• Hwang et al., “Use of human germline genes in a CDR homology-based approach to antibody humanization,” Methods, 2005, 36:35-42.Applicant
• Igawa, “Next Generation Antibody Therapeutics Using Bispecific Antibody Technology,” The Pharmaceutical Society of Japan, Jul. 1, 2017, 137(7):831-836 (with English translation).Applicant
• Igawa et al., “Generation of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X Mimicking the Function of Factor VIII Cofactor Activity,” Blood, 2012, 120(21):1126.Applicant
• Igawa et al., “VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody,” Protein Eng Des Sel, Aug. 2010, 23(8):667-677. doi: 10.1093/protein/gzq034. Epub Jun. 24, 2010.Applicant
• Igawa, “Technological Development of Bispecific Antibodies and Creation of Pharmaceuticals—with special focus on next-generation antibody therapeutics for Hemophilia,” Experimental Medicine, Technological Development of Bispecific Antibodies and Creation of Pharmaceuticals, Jul. 1, 2018, 36:1823-1829, fig. 3 (with English translation).Applicant
• Igawa, “Innovative Technology to develop Bispecific Antibody,” CSJ Current Review, Aug. 30, 2018, pp. 157-163, fig. 17-3 (with English translation).Applicant
• IMGT Scientific charts depicting the correspondence between Eu and Kabat numberings for the human IgG constant region, created May 17, 2001 and last updated Aug. 13, 2014 (Exhibit A).Applicant
• IMGT Scientific charts depicting the correspondence between Eu and Kabat numberings for the human IgG constant region, created May 17, 2001 and last updated Aug. 13, 2014 (Exhibit B).Applicant
• Ito et al., “The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values,” FEBS Lett, 1992, 309:85-88.Applicant
• Ivaskevicius et al., “Lithuanian Hemophilia A and B Register Comprising Phenotypic and Genotypic Data,” 30th Hemophilia Symposium Hamburg 1999, Springer-Verlag, Berlin, Heidelberg, 2001, 12 pages.Applicant
• Iwahashi et al., “CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity,” Mol Immunol, Oct.-Nov. 1999, 36(15-16):1079-1091.Applicant
• Jackman et al., “Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling,” J Biol Chem, Jul. 2, 2010, 285(27):20850-20859. doi: 10.1074/jbc.M110.113910. Epub May 5, 2010.Applicant
• Jain et al., “Engineering antibodies for clinical applications,” Trends Biotechnol, 2007, 25(7):307-316.Applicant
• Janeway et al., “Structure of the Antibody Molecule and Immunoglobulin Genes,” Immunobiology, 3rd ed, Garland Press, 1997, 3:1-3:11.Applicant
• Janeway et al., Chapter 3 “Antigen Recognition by B-cell and T-cell Receptors,” Immunobiology, 5th ed, 2001, pp. 93-122.Applicant
• Janeway et al., Chapter 4 “The Generation of Lymphocyte Antigen Receptors,” Immunobiology, 5th ed, 2001, pp. 123-154.Applicant
• Janeway, “The interaction of the antibody molecule with specific antigen,” Immunobiology: The Immune System in Health and Disease, 2001, section 3.6, 5 pages.Applicant
• Jendeberg et al., “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A,” J Immunol Methods, 1997, 201(1):25-34.Applicant
• Jirholt et al., “Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework,” Gene, Jul. 30, 1998, 215(2):471-476.Applicant
• Johnson et al., “Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain,” Anal Biochem, 2007, 360:75-83.Applicant
• Johnson et al., “Kabat Database and its applications: 30 years after the first variability plot,” Nucleic Acids Research, 2000, 28(1):214-218.Applicant
• Jones et al., “Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII,” Thromb Haemost, 2005, 3:991-1000.Applicant
• Joshi et al., “Avoiding antibody aggregation during processing: establishing hold times,” Biotechnol J, Sep. 2014, 9(9):1195-1205. doi: 10.1002/biot.201400052. Epub May 12, 2014.Applicant
• Jung et al., “The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody VH domains,” J Mol Biol, Jun. 8, 2001, 309(3):701-716.Applicant
• Kabat et al., Sequence of Proteins of Immunological Interest, 5th ed, 1991, pp. 690 and 693.Applicant
• Kabsch et al., “On the use of sequence homologies to predict protein structure: identical pentapeptides can have completely different conformations,” Proc Natl Acad Sci USA, Feb. 1984, 81(4):1075-1078.Applicant
• Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,” Proc Natl Acad Sci USA, 1991, 88:4363-4366.Applicant
• Kanyavuz et al., “Breaking the law: unconventional strategies for antibody diversification,” Nat Rev Immunol, Jun. 2019, 19(6):355-368. doi: 10.1038/S41577-019-0126-7.Applicant
• Karpovsky et al., “Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies,” J Exp Med, 1984, 160:1686-1701.Applicant
• Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,” Hybridoma, 1995, 14:461-473.Applicant
• Kasper et al., “A More Uniform Measurement of Factor VIII Inhibitors,” Thromb Diath Haemorrh, Dec. 15, 1975, 34(3):869-872.Applicant
• Katayose et al., “MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth,” Cancer Res, 1996, 56(18):4205-4212.Applicant
• Kenanova et al., “Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments,” Cancer Res, Jan. 15, 2005, 65(2):622-631.Applicant
• Kerschbaumer et al., “An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex,” J Biol Chem, 2004, 279(39):40445-40450.Applicant
• Khalifa et al., “Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context,” J Mol Recognit, May-Jun. 2000, 13(3):127-139.Applicant
• Khawli et al., “Improved tumor localization and radioimaging with chemically modified monoclonal antibodies,” Cancer Biother Radiopharm, 1996, 11:203-215.Applicant
• Kim et al., “Antibody Engineering for the Development of Therapeutic Antibodies,” Mol Cells, 2005, 20:17-29.Applicant
• Kim et al., “Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-tac monoclonal antibody labeled with 99mTc,” Bioconjugate Chem, 1999, 10:447-453.Applicant
• Kim et al., “Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents,” Nucl Med Biol, 2002, 29:795-801.Applicant
• Kim et al., “Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2,” Gene, 1997, 196:279-286.Applicant
• Kim et al., “Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn,” Eur J Immunol, Sep. 1999, 29(9):2819-2825.Applicant
• Kim et al., “Antibody light chain variable domains and their biophysically improved versions for human immunotherapy,” mAbs, Jan.-Feb. 2014, 6(1):219-235. doi: 10.4161/mabs.26844.Applicant
• Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J Mol Biol, Oct. 15, 1999, 293(1):41-56.Applicant
• Kipriyanov et al., “Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies,” J Mol Biol, Jun. 27, 2003, 330(1):99-111.Applicant
• Kitazawa et al., “Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa, emicizumab, depends on its ability to bridge the antigens,” Thromb Haemost, Jun. 28, 2017, 117(7):1348-1357. doi: 10.1160/TH17-01-0030. Epub Apr. 28, 2017.Applicant
• Kitazawa et al., “A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model,” Nat Med, Oct. 2012, 18(10):1570-1574. doi: 10. 1038/nm.2942. Epub Sep. 30, 2012.Applicant
• Kitazawa, “Bispecific FIX-FX antibody for bypass therapy,” 12th Workshop on Novel Technologies and Gene Transfer for Hemophilia, National Hemophilia Foundation, Oct. 24, 2014, 4 pages.Applicant
• Kitazawa, “Bispecific FIX-FX antibody for bypass therapy,” 12th NHF Workshop on New Technologies and Gene Therapies, Chugai Pharmaceutical Co., Ltd, Oct. 24, 2014, 11 pages.Applicant
• Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, Nov.-Dec. 2012, 4(6):653-663. doi: 10.4161/mabs.21379. Epub Aug. 27, 2012.Applicant
• Knoebl et al., “Emicizumab for the treatment of acquired hemophilia A,” Blood, Jan. 21, 2021, 137(3):410-419, (First Edition: Aug. 7, 2020).Applicant
• Kobayashi et al., “The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points,” Cancer Res, 1999, 59:422-430.Applicant
• Komissarov et al., “Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction,” J Biol Chem, 1997, 272(43):26864-26870.Applicant
• Kontermann, “Recombinant bispecific antibodies for cancer therapy,” Acta Pharmacol Sin, Jan. 2005, 26(1):1-9.Applicant
• Korn et al., “Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv,” J Gene Med, Jun. 2004, 6:642-651.Applicant
• Kranenborg et al., “Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma,” Cancer Res, 1995, 55:5864s-5867s.Applicant
• Kreutz et al., “Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography,” J Chromatogr B, 1998, 714:161-170.Applicant
• Krudysz-Amblo et al., “Quantitation of anti-factor VIII antibodies in human plasma,” Blood, Mar. 12, 2009, 113(11):2587-2594. doi: 10. 1182/Blood-2008-08-174987. Epub Jan. 14, 2009.Applicant
• Kroesen et al., “Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2,” Br J Cancer, 1994, 70:652-661.Applicant
• Kruse-Jarres, “Inhibitors: our greatest challenge. Can we minimize the incidence?,” Haemophilia, Jan. 2013, 19(Suppl 1):2-7. doi: 10.1111/hae. 12049.Applicant
• Kufer et al., “A revival of bispecific antibodies,” Trends Biotechnol, 2004, 22(5):238-44.Applicant
• Kumar et al., “The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C. Mutational analysis and naturally occurring variants,” J Biol Chem, Jul. 6, 2001, 276(27):24971-24977. Epub May 7, 2001.Applicant
• Kurfis et al., “Role of Arg182 in the second extracellular loop of angiotensin II receptor AT2 in ligand binding,” Biochem Biophys Res Commun, 1999, 263:816-819.Applicant
• Kurokawa et al., “Enhanced Fibrinolysis by a Bispecific Monoclonal Antibody Reactive to Fibrin and Tissue Plasminogen Activator,” Bio/Technology, 1989, 7:1163-1167.Applicant
• Labrijn et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo,” Nat Biotechnol, Aug. 2009, 27(8):767-771.Applicant
• Labrijn et al., “Controlled Fab-arm exchange for the generation of stable bispecific IgG1,” Nat Protoc, Oct. 2014, 9(10): 2450-2463. doi: 10.1038/nprot.2014.169. Epub Sep. 25, 2014.Applicant
• Labrijn et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” Proc Natl Acad Sci USA, Mar. 26, 2013, 110(13):5145-5150. doi: 10.1073/pnas.1220145110. Epub Mar. 11, 2013.Applicant
• Labrijn et al., “Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength,” J Immunol, Sep. 15, 2011, 187(6):3238-3246. doi: 10.4049/jimmunol.1003336. Epub Aug. 12, 2011.Applicant
• Lacroix-Desmazes et al, “Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A,” Blood, Jul. 15, 2008, 112(2):240-249. doi: 10.1182/blood-2008-02-124941. Epub May 9, 2008.Applicant
• Lansdorp et al., “Purification and analysis of bispecific tetrameric antibody complexes,” Mol Immunol, 1990, 27:659-666.Applicant
• Lapan et al., “Interaction of the Al Subunit of Factor VIIIa and the Serine Protease Domain of Factor X Identified by Zero-length Cross-linking,” Thromb Haemost, 1998, 80:418-422.Applicant
• Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Mol Cell Biol, 1988, 8:1247-1252.Applicant
• Le Doussal et al., “Bispecific Monoclonal Antibody-Mediated Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune Response,” J Nucl Med, 1993, 34:1662-1671.Applicant
• Le Gall et al., “Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody,” Protein Eng Des Sel, Apr. 2004, 17(4):357-366. Epub May 4, 2004.Applicant
• Lebégue et al., “Production and characterization of hybrid monoclonal antibodies with IgG1/IgG3 double isotype,” CR Acad Sci III, 1990, 310(9):377-382.Applicant
• Lenting et al., “The life cycle of coagulation factor VIII in view of its structure and function,” Blood, 1998, 92(11):3983-3996.Applicant
• Leong et al., “Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation,” 2001, Cytokine, 16(3):106-119.Applicant
• Lescar et al., “Crystal Structure of a Cross-reaction Complex between Fab 59.13.7 and Guinea Fowl Lysozyme,” Journal of Biological Chemistry, 1995, 270(30):18067-18076.Applicant
• Li et al., “Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions,” Immunology, Dec. 2005, 116(4):487-498.Applicant
• Life Technologies (Invitrogen: “ecdysone analogue” and pIND plasmid), Aug. 10, 2012, 2 pages.Applicant
• Lillicrap, “von Willebrand disease: advances in pathogenetic understanding, diagnosis and therapy,” Blood, Nov. 28, 2013, 122(23):3735-3740. doi: 10.1182/blood-2013-06-498303. Epub Sep. 24, 2013.Applicant
• Lin et al., “Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor,” J Pharmacol Exp Ther, 1999, 288(1):371-378.Applicant
• Lindhofer et al., “Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas,” J Immunol, 1995, 155:219-225.Applicant
• Lindsay, Chapter 4 “Determination of the Kinetics and Mechanism of tg-FIX Activation by Factor XIa,” 2004, pp. 49-75.Applicant
• Link et al., “Production and Characterization of a Bispecific IgG Capable of Inducing T-Cell-Mediated Lysis of Malignant B Cells,” Blood, 1993, 81:3343-3349.Applicant
• Liu et al., “Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association,” Biochem J, Sep. 1, 2001, 358(Pt 2):511-516.Applicant
• Liu et al., “Heterogeneity of monoclonal antibodies,” J Pharm Sci, 2008, 97(7):2426-2447.Applicant
• Lloyd et al., “The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma,” J Natl Med Assoc, Oct. 1991, 83(10):901-904.Applicant
• Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng Des Sel, Mar. 2009, 22(3):159-168. doi: 10.1093/protein/gzn058. Epub Oct. 29, 2008.Applicant
• Lobo et al., “Antibody pharmacokinetics and pharmacodynamics,” J Pharm Sci, 2004, 93:2645-2668.Applicant
• Löfqvist et al., “Haemophilia prophylaxis in young patients—a long-term follow-up,” J Intern Med, 1997, 241:395-400.Applicant
• Lu et al., “Di-diabody: a novel tetravalent bispecific antibody molecule by design,” J Immunol Methods, 2003, 279:219-232.Applicant
• Lu et al., “Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments,” J Immunol Methods, 2002, 267:213-226.Applicant
• Lund et al., “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” The Journal of Immunology, Dec. 1, 1996, 157(11):4963-4969.Applicant
• MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol, 1996, 262:732-745.Applicant
• Maeda et al., “Novel Antibody Modification Techniques and their Application to Antibody Therapeutics,” Farumashia, 2015, vol. 51, pp. 424-428 (with English translation).Applicant
• Mahlangu et al., “Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors,” N Engl J Med, Aug. 30, 2018, 379(9):811-822.Applicant
• Maini et al., “Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate,” Arthritis Rheum, 2006, 54:2817-2829.Applicant
• Maity et al., “Equilibrium unfolding of dimeric and engineered monomeric forms of Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate,” Arch Biochem Biophys, Feb. 1, 2005, 434(1):93-107.Applicant
• Male et al., “Antibodies,” Immunology, 7th ed, Elsevier Ltd., 2006, pp. 59-86.Applicant
• Manco-Johnson et al., “Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia,” N Engl J Med, Aug. 9, 2007, 357(6):535-544.Applicant
• Manz et al., Bioanalytical Chemistry, World Scientific Publishing Co., 2003.Applicant
• Manzke et al., “Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography,” J Immunol Methods, 1997, 208:65-73.Applicant
• Mariuzza, “The Structural Basis of Antigen-Antibody Recognition,” Annu Rev Biophys Chem, 1987, 16:139-159.Applicant
• Marshall et al., “Rational design and engineering of therapeutic proteins,” Drug Discov Today, Mar. 1, 2003, 8(5):212-221.Applicant
• Marti et al., “Inverse electrostatic effect: electrostatic repulsion in the unfolded state stabilizes a leucine zipper,” Biochemistry, 2004, 43(39):12436-12447.Applicant
• Martin et al., “Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding,” Mol Cell, 2001, 7:867-877.Applicant
• Marvin et al., “Recombinant approaches to IgG-like bispecific antibodies,” Acta Pharmacol Sin, 2005, 26:649-658.Applicant
• Marvin et al., “Redesigning an antibody fragment for faster association with its antigen,” Biochemistry, 2003, 42:7077-7083.Applicant
• Massino et al., “Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay,” J Immunol Methods, 1997, 201:57-66.Applicant
• Mazor et al., “Improving target cell specificity using a novel monovalent bispecific IgG design,” mAbs, Mar./Apr. 2015, 7(2):377-389.Applicant
• McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature, 1990, 348:552-554.Applicant
• McPhee et al., “Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation,” Proc Natl Acad Sci USA, Oct. 15, 1996, 93(21):11477-11481.Applicant
• Medesan et al., “Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1,” J Immunol, Mar. 1, 1997, 158(5):2211-2217.Applicant
• Menegatti et al., “Factor X Deficiency,” Semin Thromb Hemost, 2009, 35:407-415.Applicant
• Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol, 1998, 16:677-681.Applicant
• Mertens et al., “Factor VIII-Factor IX Interactions: Molecular Sites Involved in Enzyme-Cofactor Complex Assembly,” Thromb Haemost, 1999, 82:209-217.Applicant
• Michaelsen et al., “A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells,” Eur J Immunol, Jan. 2006, 36(1):129-138.Applicant
• Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, 1983, 305:537-540.Applicant
• Minami et al., “Bispecific Antibody ACE910 Improves Coagulation Function in Plasma of Patients with Factor XI-Deficiency,” Japanese Journal of Thrombosis and Hemostasis, 2015, 26(2):188, 0-024 (with English translation).Applicant
• Miyata, “Factor IX Abnormality—Molecular Defects of Factor IX,” Japanese Journal of Thrombosis and Hemostasis, 1991, 2(1):1-11 (with English translation).Applicant
• Miyazaki et al., “Generation of bispecific IgG, which mimics the cofactor function of blood coagulation factor VIII,” Seikagaku, Poster Sessions (2P-B-161), 2006.Applicant
• Mohan, “Calbiochem® Buffers—A guide for the preparation and use of buffers in biological systems,” EMD Biosciences, Inc., an Affiliate of Merck KGaA, Darmstadt, DE, 2003, 37 pages.Applicant
• Mohnle et al., “Emicizumab in the Treatment of Acquired Haemophilia: A Case Report,” Transfus Med Hemother, Apr. 2019, 46(2):121-123.Applicant
• Morell et al., “Metabolic properties of IgG subclasses in man,” J Clin Invest, 1970, 49(4):673-680.Applicant
• Morimoto et al., “Single-step purification of F(ab′)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSK gel Phenyl-5PW,” J Biochem Biophys Methods, 1992, 24:107-117.Applicant
• Morris, “Epitope Mapping of Protein Antigens by Competition ELISA,” The Protein Protocols Handbook, Jan. 1, 1996, pp. 595-600.Applicant
• Morrison, “Two heads are better than one,” Nat Biotechnol, Nov. 2007, 25(11):1233-1234.Applicant
• Muller et al., “The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies,” FEBS Lett, Jan. 30, 1998, 422(2):259-264.Applicant
• Murata et al., “Anti-Digoxin Fab Variants Generated by Phage Display,” Mol Biotechnol, Jun. 2013, 54(2):269-277. doi : 10. 1007/s12033-012-9564-1.Applicant
• Murray et al., Chapter 55 “Blood plasma and coagulation process,” Human Biochemistry, Moscow:Mir, 2009, 2:328-329 (with English translation).Applicant
• Muto et al., “Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation,” J Thromb Haemost, Feb. 2014, 12(2):206-213. doi: 10. 1111/jth.12474.Applicant
• Muto et al., “Anti-factor IXa/X bi specific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation,” Supporting Information to J Thromb Haemost, Feb. 2014, 12(2):206-213, printed from the Internet at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fjth.12474&attachmentId=2210006855.Applicant
• Muto et al., “Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A,” Blood, Nov. 13, 2014, 124(20):3165-3171. doi: 10. 1182/blood-2014-07-585737. Epub Oct. 1, 2014.Applicant
• Muto et al., “Hemostatic Effect of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X in an Acquired Hemophilia A Model,” Blood, 2012, 120(21):42, 6 pages.Applicant
• Muto et al., “Preventive effect of a bispecific antibody ACE910 that mimics the function of factor VIII on joint bleeding in a model of hemophilia A,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 16, 2014, 3 pages (with English translation).Applicant
• Muto et al., “Preventive effect of a bispecific antibody ACE910 that mimics the function of factor VIII on joint bleeding in a model of hemophilia A,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 30, 2014, 14 pages (with English translation).Applicant
• Muto et al., “Preventive effect of a humanized bispecific antibody to factors IXa and X (ACE910) on spontaneous joint bleeding in a non-human primate model of hemophilia A,” Haemophilia, 2014, 20(Suppl 3):76.Applicant
• Muto et al., “Preventive effect of a humanized bispecific antibody to factors IXa and X (ACE910) on spontaneous joint bleeding in a non-human primate model of hemophilia A,” Meeting World Federation of Hemophilia, 2014 World Congress, May 14, 2014, 14 pages.Applicant
• Muto et al., “Preventive Effect of Bispecific Antibody ACE910 that functionally substitutes for Factor VIII on Intraarticular Bleeding in Hemophilia A Models,” Japanese Journal of Thrombosis and Hemostasis, 2014, 25(2):244, 0-016 (with English translation).Applicant
• Narhi et al., “Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin,” Protein Eng, Feb. 2001, 14(2):135-140.Applicant
• “National Haemophilia Foundation (NHF) Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Prophylaxis,” Medical Bulletin, 1994, No. 193, 1 page.Applicant
• Nesterova et al., “Glypican-3 as a novel target for an antibody-drug conjugate,” AACR Abstract No. 656, Los Angeles, CA, Apr. 4-18, 2007.Applicant
• Nieba et al., “Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment,” Protein Eng, Apr. 1997, 10(4):435-444.Applicant
• Nilsson et al., “Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies,” Proc Natl Acad Sci USA, 1986, 83:9169-9173.Applicant
• Nilsson et al., “Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B,” J Intern Med, 1992, 232:25-32.Applicant
• Nishimoto et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, 2005, 106:2627-2632.Applicant
• Nishimoto et al., “Interleukin 6: from bench to bedside,” Nat Clin Pract Rheumatol, 2006, 2:619-626.Applicant
• Nishimura et al., “Factor IX Fukuoka. Substitution of ASN92 by his in the second epidermal growth factor-like domain results in defective interaction with factors VIIIa/X,” Journal of Biological Chemistry, 1993, 268(32):24041-24046.Applicant
• Nitta et al., “Preliminary trial of specific targeting therapy against malignant glioma,” Lancet, 1990, 335:368-371.Applicant
• Nogami, “Bispecific Antibody that Substitutes for Factor VIII in the Treatment of Childhood Hemophilia A,” The Japanese Journal of Pediatric Hematology/Oncology, 2016, 53(2):69-74 (with English translation).Applicant
• Nohaile et al., “Altering dimerization specificity by changes in surface electrostatics,” Proc Natl Acad Sci USA, Mar. 13, 2001, 98(6):3109-3114. Epub Feb. 27, 2001.Applicant
• O'Shea et al., “Peptide ‘Velcro’: design of a heterodimeric coiled coil,” Curr Biol, Oct. 1, 1993, 3(10):658-667.Applicant
• Ogiwara et al., “Anti FIXa/FX Bispecific Antibody (Emicizumab) Enhances Plasma Procoagulant Activity in Hemophilia B in the Presence of Very Low Level of Factor IX,” Res Pract Thromb Haemost, 2017, 1(suppl 1):749.Applicant
• Okubo et al. “The production and characterization of four monoclonal antibodies to human factor X,” Nara Med Assoc, 1987, 38(1):20-28.Applicant
• Oldenburg et al., “Emicizumab Prophylaxis in Hemophilia A with Inhibitors,” The New England Journal of Medicine, Aug. 2017, 377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub Jul. 10, 2017.Applicant
• Oldenburg, “Prophylaxis in bleeding disorders,” Thromb Res, Jan. 2011, 127(Suppl 1):S14-S17. doi: 10. 1016/j. thromres.2010. 10.005. Epub Nov. 26, 2010.Applicant
• Onda et al., “Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity,” Cancer Res, 2001, 61:5070-5077.Applicant
• Ono et al., “The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity,” Mol Immunol, 1999, 36(6):387-395.Applicant
• Otomo et al., “Structure of the heterodimeric complex between CAD domains of CAD and ICAD,” Nat Struct Biol, Aug. 2000, 7(8):658-662. doi: 10.1038/77957. PMID: 10932250.Applicant
• Ozhegov et al., Tolkovyi Slovar Russkogo iazyka: 2004, p. 292 (with an English translation of the relevant passage defining “control”).Applicant
• Pabst et al., “Engineering of novel Staphylococcal Protein A ligands to enable milder elution pH and high dynamic binding capacity,” J Chromatogr A. Oct. 3, 2014, 1362:180-185. doi: 10.1016/j.chroma.2014.08.046. Epub Aug. 19, 2014.Applicant
• Pabst et al., “Evaluation of recent Protein A stationary phase innovations for capture of biotherapeutics,” J Chromatogr A, Jun. 15, 2018, 1554:45-60. doi: 10.1016/j.chroma.2018.03.060. Epub Apr. 7, 2018.Applicant
• Pakula et al., “Genetic Analysis of Protein Stability and Function,” Annu Rev Genet, 1989, 23:289-310.Applicant
• Pan et al., “Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth,” Cancer Cell, Jan. 2007, 11(1):53-67.Applicant
• Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proc Natl Acad Sci USA, 1988, 85(9):3080-3084.Applicant
• Pardridge et al., “Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization,” J Pharm Sci, Aug. 1995, 84(8):943-948.Applicant
• Pardridge et al., “Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein,” J Pharmacol Exp Ther, 1998, 286(1):548-554.Applicant
• Paul, Chapter 8 “Immunogenicity and Antigen Structure,” Fundamental Immunology, 3rd ed, Raven Press NY, 1993, p. 242.Applicant
• Pavlinkova et al., “Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis,” Nucl Med Biol, 1999, 26:27-34.Applicant
• Pavlou et al., “The therapeutic antibodies market to 2008,” Eur J Pharm Biopharm, 2005, 59:389-396.Applicant
• Peipp et al., “Bispecific antibodies targeting cancer cells,” Biochem Soc Trans, Aug. 2002, 30:507-511.Applicant
• Pejchal et al., “A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies,” J Virol, Sep. 2009, 83(17):8451-8462. doi: 10.1128/JVI.00685-09. Epub Jun. 10, 2009.Applicant
• Peters et al., “Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability,” J Biol Chem, Jul. 13, 2012, 287(29):24525-24533. doi: 10.1074/jbc.M112.369744. Epub May 18, 2012.Applicant
• Piper et al., “Interferon therapy in primary care,” Primary Care Update for Ob/Gyns, 2001, 8(4):163-169.Applicant
• Poduslo et al., “Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers,” J Neurochem, 1996, 66:1599-1609.Applicant
• Pokkuluri et al., “A domain flip as a result of a single amino-acid substitution,” Structure, Aug. 15, 1998, 6(8):1067-1073.Applicant
• Pons et al., “Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction,” Protein Sci, 1999, 8(5):958-968.Applicant
• Portolano et al., “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain ‘Roulette’,” J Immunol, 1993, 150(3):880-887.Applicant
• Presta, “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Adv Drug Deliv Rev, 2006, 58(5-6):640-656.Applicant
• Price et al., “Tissue factor and tissue factor pathway inhibitor,” Anaesthesia, 2004, 59:483-492.Applicant
• Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci USA, 1989, 86(24):10029-10033.Applicant
• Raffen et al., “Reengineering immunoglobulin domain interactions by introduction of charged residues,” Protein Eng, Apr. 1998, 11:303-309.Applicant
• Raghavan et al., “Fc Receptors and Their Interactions with Immunoglobulins,” Annu Rev Cell Dev Biol, Nov. 1996, 12:181-220.Applicant
• Rajagopal et al., “Trehalose Limits Fragment Antibody Aggregation and Influences Charge Variant Formation in Spray-Dried Formulations at Elevated Temperatures,” Mol Pharm, Jan. 7, 2019, 16(1):349-358. doi: 10.1021/acs.molpharmaceut.8b01002. Epub Dec. 17, 2018.Applicant
• Rajpal et al., “A general method for greatly improving the affinity of antibodies by using combinatorial libraries,” Proc Natl Acad Sci USA, 2005, 102:8466-8471.Applicant
• Rallapalli et al., “An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B,” Journal of thrombosis and haemostasis, Jul. 2013, 11(7):1329-1340. doi:10.1111/jth.12276.Applicant
• Raposo et al., “Epitope-specific antibody response is controlled by immunoglobulin Vh polymorphisms,” J Exp Med, Mar. 10, 2014, 211(3):405-411. doi: 10.1084/ jem.20130968. Epub Feb. 17, 2014.Applicant
• Reddy et al., “Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4,” J Immunol, 2000, 164(4):1925-1933.Applicant
• Reference table: IMGT exon, EU and Kabat numbering of residues within the human 1gG1 sequence; retrieved from the Internet at http:/www.imgt.org/IMGTScientificChart/Numbering/Hu_1GHGnber.html on Jun. 1, 2020, 4 pages (cited by the opponents in the EPO opposition proceedings of EP 3 050 963, which was notified to the patentee on Jul. 3, 2020).Applicant
• Reichert et al., “Development trends for monoclonal antibody cancer therapeutics,” Nat Rev Drug Discov, 2007, 6(5):349-356.Applicant
• Reichert et al., “Monoclonal antibody successes in the clinic,” Nat Biotechnol, 2005, 23:1073-1078.Applicant
• Reimann et al., “A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties,” AIDS Res Hum Retroviruses, Jul. 20, 1997, 13(11):933-943.Applicant
• Retout et al., “Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A,” Clin Pharmacokinet, Dec. 2020, 59(12):1611-1625. Epub Jun. 5, 2020.Applicant
• Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng, 1996, 9:617-621.Applicant
• Rispens et al., “Mechanism of Immunoglobulin G4 Fab-arm Exchange,” J Am Chem Soc, Jul. 6, 2011, 133(26):10302-10311. doi: 10.1021/ja203638y. Epub Jun. 15, 2011.Applicant
• Rispens et al., “Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange,” J Biol Chem, Feb. 28, 2014, 289(9):6098-6109. doi: 10.1074/jbc.M113.541813. Epub Jan. 14, 2014.Applicant
• Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc Natl Acad Sci USA, 1994, 91:969-973.Applicant
• Roitt et al., Chapter 3 “Antibodies,” Immunology, M:Mir, 5th ed, 2000, pp. 97-113 (with what are believed to be the corresponding pages from an English version of Immunology).Applicant
• Roitt et al., “Antibodies and their Receptors,” Immunology, 5th ed, 1998, pp. 80-81.Applicant
• Roopenian et al., “FcRn: the neonatal Fc receptor comes of age,” Nat Rev Immunol, Sep. 2007, 7(9):715-725.Applicant
• Rothe et al., “Ribosome display for improved biotherapeutic molecules,” Expert Opin Biol Ther, 2006, 6:177-187.Applicant
• Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA, Mar. 1982, 79(6):1979-1983.Applicant
• Ruef et al., “A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation,” Thromb Haemost, 1999, 82(1):109-114.Applicant
• Ruf et al., “Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab,” J Clin Oncol, 2008, 26(May 20 Suppl):abstract 14006.Applicant
• Ruggeri et al., “von Willebrand Factor and van Willebrand Disease,” Blood, Oct. 1987, 70(4): 895-904.Applicant
• Ryman et al., “Pharmacokinetics of Monoclonal Antibodies,” CPT Pharmacometrics Syst Pharmacol, Sep. 2017, 6(9):576-588. doi: 10.1002/psp4.12224. Epub Jul. 29, 2017.Applicant
• Saenko et al., “Molecular defects in coagulation Factor VIII and their impact on Factor VIII function,” Vox Sang, Aug. 2002, 83(2):89-96.Applicant
• Saito et al., “Establishment of Factor VIII Mimetic Antibodies and Their In Vitro Activities in Hemophilia A,” 2006 National Hemophilia Foundation Symposia, 1 page.Applicant
• Saito et al., “Factor VIII Mimetic Antibody: (1) Establishment and Characterization of Anti-factor IX/anti-factor X Bispecific Antibodies,” 2005 International Society of Thrombosis and Haemostasis, 1 page.Applicant
• Sakai et al., “Guidelines for the management of acquired hemophilia A: 2017 revision,” Jpn J Thromb Hemost, 2017, 28(6):715-747 (with English translation).Applicant
• Salfeld et al., “Isotype selection in antibody engineering,” Nat Biotechnol, 2007, 25:1369-1372.Applicant
• Sal-Man et al., “Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo,” Biochem J, 2005, 385:29-36.Applicant
• Sampei et al., “Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity,” PLoS One, 2013, 8(2):e57479, 13 pages. doi: 10.1371/journal.pone.0057479. Epub Feb. 28, 2013.Applicant
• Sampei et al., “Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity,” mAbs, 2015, 7(1):120-128. doi: 10.4161/19420862.2015.989028.Applicant
• Sarkar et al., “Rational cytokine design for increased lifetime and enhanced potency using pH-activated ‘histidine switching’,” Nat Biotechnol, Sep. 2002, 20(9):908-913. Epub Aug. 5, 2002.Applicant
• Sato et al., “Properties of Two VEGF Receptors, Flt-1 and KDR, in Signal Transduction,” Ann NY Acad Sci, May 2000, 902:201-207, discussion pp. 205-207.Applicant
• Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer Res, 1993, 53:851-856.Applicant
• Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci USA, Jul. 5, 2011, 108(27):11187-11192. doi: 10.1073/pnas.1019002108. Epub Jun. 20, 2011.Applicant
• Schaeffer et al., “The Rat Glomerular Filtration Barrier Does Not Show Negative Charge Selectivity,” Microcirculation, 2002, 9:329-342.Applicant
• Schmidt et al., “Structure-function relationships in factor IX and factor IXa,” Trends Cardiovasc Med, Jan. 2003, 13(1):39-45.Applicant
• Schmidt et al., Chapter 18, Section 18.6, “Hemostasis and Coagulation,” Human Physiology, 2nd ed, Springer-Verlag, 1989, pp. 418-423.Applicant
• Schmidt et al., Chapter 29, “Enzymes of the pancreatic juice,” Human Physiology, 2nd ed, Springer-Verlag, 1989, p. 716.Applicant
• Schmidt et al., Chapter 18, Section 18.6, “Hemostasis and Coagulation,” Human Physiology, Moscow, 1996, 2:431-436 (with what are believed to be the corresponding pages from an English version of Human Physiology).Applicant
• Schmidt et al., Chapter 29, “Enzymes of the pancreatic juice,” Human Physiology, Moscow, 1996, 3:764 (with what are believed to be the corresponding pages from an English version of Human Physiology).Applicant
• Schmitz et al., “Phage display: a molecular tool for the generation of antibodies—a review,” Placenta, 2000, 21(Suppl A):S106-S112.Applicant
• Schuurman et al., “Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites,” Immunology, Aug. 1999, 97(4):693-698.Applicant
• Schuurman et al., “The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds,” Mol Immunol, Jan. 2001, 38(1):1-8.Applicant
• Screenshots of Genetyx software, 3 pages (document cited by opponent during the EPO opposition proceedings of EP 2 202 245 on May 22, 2020).Applicant
• Screenshots of the web-based calculator, 9 pages (document cited by opponent during the EPO opposition proceedings of EP 2 202 245 on May 22, 2020).Applicant
• Sections of the Genetyx manual pertaining to isoelectric point, 5 pages (with English translation) (document cited by opponent during the EPO opposition proceedings of EP 2 202 245 on May 22, 2020).Applicant
• Segal et al., “Bispecific antibodies in cancer therapy,” Curr Opin Immunol, 1999, 11:558-562.Applicant
• Segal et al., “Introduction: bispecific antibodies,” J Immunol Methods, 2001, 248:1-6.Applicant
• Sequence alignments and modification scheme, 3 pages (document filed during Oral Proceedings and mentioned in minutes of the Oral Proceedings posted by EPO on Jul. 25, 2018).Applicant
• Shalaby et al., “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene,” J Exp Med, 1992, 175:217-225.Applicant
• Sharifi et al., “Improving monoclonal antibody pharmacokinetics via chemical modification,” Q J Nucl Med, Dec. 1998, 42(4):242-249.Applicant
• Shaul, “Exploring the charge space of protein-protein association: a proteomic study,” Proteins, 2005, 60:341-352.Applicant
• Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem, 2001, 276:6591-6604. Epub Nov. 28, 2000.Applicant
• Shima, “The Forefront and Prospects of Hemophilia Treatment,” The Journal of the Japan Pediatric Society, Mar. 1, 2017, 121(3):543-552 (with English translation).Applicant
• Shima et al., “691 Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study,” 56th ASH Annual Meeting and Exposition, Dec. 2014, 2 pages, printed from the Internet at https://ash.confex.com/ash/2014/webprogram/Paper67797. Html.Applicant
• Shima et al., “Pharmacokinetics and Pharmacodynamic Response of Bispecific Antibody ACE910 which Functionally Substitutes for Factor VIII Cofactor, in Healthy Adults,” Japanese Journal of Thrombosis and Hemostasis, 2014, 25(2):245, 0-017 (with English translation).Applicant
• Shima et al., “Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study,” Blood, Nov. 6, 2014, 124:691.Applicant
• Shima et al., “The pharmacokinetic and pharmacodynamic profiles of ACE910, a bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 30, 2014, 12 pages (with English translation).Applicant
• Shima et al., “The pharmacokinetic and pharmacodynamic profiles of ACE910, a bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 16, 2014, 13 pages (with English translation).Applicant
• Shima et al., “The safety, tolerability, pharmacokinetic and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function demonstrated in healthy adults,” Haemophilia, 2014, 20(Suppl 3):76.Applicant
• Shima et al., “Factor VIII Mimetic Antibody: (2) In Vitro Assessment of Cofactor Activity in Hemophilia A,” 2005 International Society of Thrombosis and Haemostasis, 3(Suppl s1):P0038.Applicant
• Shima et al., Factor VIII Mimetic Antibody: (2) In Vitro Assessment of Cofactor Activity in Hemophilia A, Rinsho Ketsueki, 2005, 46(8):777.Applicant
• Shima, Bi-Specific Antibodies as FVIII Mimetics in Hemophilia, Jun. 10, 2014, 118 pages, printed from the Internet at https://www.isth.org/page/2014Microsite/?, https://www.isth.org/page/2014FinalProgram? and http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/Microsite/Milwaukee_Final_Program_6614.pdf.Applicant
• Shima, “Bi-Specific Antibodies as FVIII Mimetics in Hemophilia,” ISTH 2014 SSC, Jun. 25, 2014, 25 pages.Applicant
• Shima, “New hemophilia treatment by a biospecific antibody to factors IXa and X,” The 76th Annual Meeting of the Japanese Society of Hematology, Nov. 1, 2014, 4 pages (with English translation).Applicant
• Shima, “New hemophilia treatment by a bispecific antibody to factors IXa and X,” The 76th Annual Meeting of the Japanese Society of Hematology, Oct. 23, 2014, 15 pages.Applicant
• Shima, “New hemophilia treatment by a bispecific antibody to factors IXa and X,” Oct. 24, 2014, 11 pages, printed from the Internet at https://www.meeting-schedule.com/76jsh/schedule (with English abstract).Applicant
• Shima, “New hemophilia treatment by a bispecific antibody to factors IXa and X,” The Japanese Journal of Clinical Hematology, 2014, 55(9):236.Applicant
• Shima, “Novel Bypassing Agents-novel bypass and adjunctive therapies,” World Federation of Hemophilia 2014 World Congress, May 15, 2014, 16 pages.Applicant
• Shima, “Progress in Pathological Analysis of Hemophilia A,” Japanese Journal of Thrombosis and Hemostasis, 2014, 25(2):144 (with English translation).Applicant
• Shima, “Progress in the Pathological Analysis of Hemophilia A,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 16, 2014, 2 pages (with English translation).Applicant
• Shima, “Progress in the Pathological Analysis of Hemophilia A,” The 36th Congress of the Japanese Society on Thrombosis and Hemostasis, May 31, 2014, 5 pages (with English translation).Applicant
• Shima, “The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function demonstrated in healthy adults,” World Federation of Hemophilia 2014 World Congress, May 14, 2014, 10 pages.Applicant
• Shima et al., “Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors,” Blood Adv, Sep. 27, 2017, 1(22):1891-1899. doi: 10.1182/bloodadvances.2017006684. eCollection Oct. 10, 2017.Applicant
• Shima et al., “Long-term safety and prophylactic efficacy of once weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study,” J Thromb Haemost, Jun. 2015, 13( Suppl 2):6-7, abstract AS017.Applicant
• Shima, “How to treat patients with severe haemophilia A without FVIII concentrates? New concepts in haemophilia therapy (bi-specific antibody mimicking VIII),” Haemophilia, 2015, 21(Suppl 2):7-8.Applicant
• Shima, M., “Bispecific antibodies to coagulation factors IXa and X mimic the function of factor VIII,” Haemophilia, 2006, 12(Suppl 2):98.Applicant
• Shima et al., “Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A,” NEJM, May 2016, 374(21):2044-2053. doi: 10.1056/NEJMoa1511769.Applicant
• Shirahata, “5. Future Prospects. 1) Direction for Improvement of Coagulation Factor Preparations,” Iyaku (Medicine and Drug) Journal Co., Ltd., Jan. 15, 2009, pp. 280-289 (with English translation).Applicant
• Shire et al., “Challenges in the development of high protein concentration formulations,” J Pharm Sci, 2004, 93:1390-1402.Applicant
• Singer et al., “Structure of Proteins,” Genes & Genomes, Moscow, Mir, 1998, pp. 63-64 (with what are believed to be the corresponding pages from an English version of Genes & Genomes).Applicant
• Singer et al., “Structure of Proteins,” Genes & Genomes, 1991, pp. 67-70.Applicant
• Sinha et al., “Electrostatics in protein binding and function,” Curr Protein Pept Sci, 2002, 3(6):601-614.Applicant
• Sinha et al., “Molecular dynamics simulation of a high-affinity antibody-protein complex: the binding site is a mosaic of locally flexible and preorganized rigid regions,” Cell Biochem Biophys, 2005, 43:253-273.Applicant
• Skerra, “Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli,” Gene, Dec. 30, 1994, 151(1-2):131-135.Applicant
• Smans et al., “Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens,” Int J Cancer, 1999, 83:270-277.Applicant
• Smith, “Creative Expression: Mammalian Expression Vectors and Systems,” The Scientist Magazine, Feb. 2, 1998, pp. 1-3.Applicant
• Soeda et al., “Factor VIII Mimetic Antibody: (1) Establishment of Anti-FIXa/FX Bispecific Antibodies,” Rinsho Ketsueki, Aug. 30, 2005, 46(8):728 (with English translation).Applicant
• Soeda et al., “FVIII-Mimetic Action of Anti-FIXa/Anti-FX Bispecific Antibodies Produced by the Phage Library Method,” Jpn J Thromb Hemost, Oct. 1, 2005, 16(5):526 (with English translation).Applicant
• Spiess et al., “Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies,” Nat Biotechnol, Aug. 2013, 31(8):753-758. doi: 10.1038/nbt.2621. Epub Jul. 7, 2013.Applicant
• Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth,” Proc Nat Acad Sci USA, 1991, 88:8691-8695.Applicant
• Staerz et al., “Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity,” Proc Natl Acad Sci USA, 1986, 83:1453-1457.Applicant
• Stickney et al., “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,” Cancer Res, 1991, 51:6650-6655.Applicant
• Strand et al., “Biologic therapies in rheumatology: lessons learned, future directions,” Nat Rev Drug Discov, 2007, 6:75-92.Applicant
• Summary of information about antibodies in examples of patent, 3 pages (document submitted in EPO opposition proceedings and posted by EPO on Apr. 13, 2018).Applicant
• Supplemental Material to Raposo et al., “Epitope-specific antibody response is controlled by immunoglobulin VH polymorphisms,” J Exp Med, Mar. 10, 2014, 211(3):405-11. doi: 10.1084/jem.20130968. Epub Feb. 17, 2014, 4 pages (submitted by the Patentee during EPO opposition proceedings of EP 2 202 245 on May 24, 2019).Applicant
• Suresh et al., “Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays,” Proc Natl Acad Sci USA, 1986, 83:7989-7993.Applicant
• Suresh et al., “Bispecific monoclonal antibodies from hybrid hybridomas,” Methods Enzymol, 1986, 121:210-228.Applicant
• Tabrizi et al., “Elimination mechanisms of therapeutic monoclonal antibodies,” Drug Discov Today, Jan. 2006, 11(1-2):81-88.Applicant
• Takeyama et al., “An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A,” J Thromb Haemost, Apr. 2020, 18(4):825-833.Applicant
• Taki, The Journal of Japanese Society on Thrombosis and Hemostasis, 2002, 13:109-113.Applicant
• Tamura et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,” J Immunol, Feb. 1, 2000, 164(3):1432-1441.Applicant
• Tan et al., “Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency,” Biophys J, Sep. 1998, 75(3):1473-1482.Applicant
• Tan et al., “Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility,” Immunotechnology, 1998, 4(2):107-114.Applicant
• Tarantino et al., “Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report,” Haemophilia, Sep. 2007, 13(5):663-669.Applicant
• Tarditi et al., “Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies,” J Chromatogr, 1992, 599:13-20.Applicant
• Taylor et al., “A new era for hemophilia B treatment,” Blood, Apr. 7, 2016, 127(14):1734-1736.Applicant
• Teeling et al., “The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20,” J Immunol, 2006, 177(1):362-371.Applicant
• Ten Kate et al., “Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG,” Eur J Nucl Med, 1990, 17:305-309.Applicant
• Tian et al., “In-depth analysis of subclass-specific conformational preferences of IgG antibodies,” IUCrJ, Jan. 1, 2015, 2(Pt 1):9-18. doi: 10.1107/S205225251402209X. eCollection Jan. 1, 2015.Applicant
• Tsurushita et al., “Design of humanized antibodies: From anti-Tac to Zenapax,” Methods, 2005, 36:69-83.Applicant
• Uchida et al., “A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects,” Blood, Mar. 2016, 127(13):1633-1641. doi: 10.1182/blood-2015-06-650226. Epub Dec. 1, 2015.Applicant
• Uchida et al., “First-In-Human Trial of Bispecific Antibody ACE910 Having Factor VIII-Substituting Activity, Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Adults,” Jpn J Clin Pharmacol Ther, 2014, 45 Suppl:S297.Applicant
• Vaisitti et al., “Cationization of monoclonal antibodies: another step towards the ‘magic bullet’?,” J Biol Regul Homeost Agents, 2005, 19(3-4):105-112.Applicant
• Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J Mol Biol, 2002, 320(2):415-428.Applicant
• Van Den Abbeele et al., “Antigen-Binding Site Protection During Radiolabeling Leads to a Higher Immunoreactive Fraction,” J Nucl Med, Jan. 1991, 32(1):116-122.Applicant
• Van Der Neut Kolfschoten et al., “Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange,” Science, Sep. 14, 2007, 317(5844):1554-1557.Applicant
• Van Walle et al., “Immunogenicity screening in protein drug development,” Expert Opin Biol Ther, 2007, 7(3):405-418.Applicant
• Van Loghem et al., “Staphylococcal protein A and human IgG subclasses and allotypes,” Scand J Immunol, 1982, 15(3):275-278.Applicant
• Vargas-Madrazo et al., “An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues,” J Mol Recognit, May-Jun. 2003, 16(3):113-120.Applicant
• Vaughan et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nat Biotechnol, Mar. 1996, 14(3):309-314.Applicant
• Vehar et al., “Structure of human factor VIII,” Nature, Nov. 22, 1984, 312(5992):337-342.Applicant
• Verbruggen et al., “The Nijmegen Modification of the Bethesda Assay for Factor VIII: C Inhibitors: Improved Specificity and Reliability,” Thromb Haemost, Feb. 1995, 73(2):247-251.Applicant
• Verhoeyen et al., “Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody,” Immunology, Mar. 1993, 78(3):364-370.Applicant
• Verhoeyen et al., Chapter 5 “Monoclonal Antibodies in Clinical Oncology,” 1991, ed. AA Epenetos, Chapman and Hall, pp. 37-43.Applicant
• Wagenvoord et al., “Development of a Simple Chromogenic Factor VIII Assay for Clinical Use,” Haemostasis, 1989, 19(4):196-204.Applicant
• Wang et al., “Conserved amino acid networks involved in antibody variable domain interactions,” Proteins, Jul. 2009, 76(1):99-114. doi: 10.1002/prot.22319.Applicant
• Wang et al., “Antibody Structure, Instability, and Formulation,” Journal of Pharmaceutical Sciences, Jan. 2007, 96(1):1-26.Applicant
• Ward et al., “Effects of engineering complementary charged residues into the hydrophobic subunit interface of tyrosy1-tRNA synthetase. Appendix: Kinetic analysis of dimeric enzymes that reversibly dissociate into inactive subunits,” Biochemistry, Jun. 30, 1987, 26(13):4131-4138.Applicant
• Warnaar et al., “Purification of bispecific F(ab′)2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer,” Hybridoma, 1994, 13:519-526.Applicant
• Weiner et al., “A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16,” Cancer Res, 1993, 53:94-100.Applicant
• Weiner et al., “The Role of T Cell Activation in Anti-CD3 × Antitumor Bispecific Antibody Therapy,” J Immunol, 1994, 152:2385-2392.Applicant
• Wenig et al., “Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG,” Proc Natl Acad Sci, Dec. 14, 2004, 101:17371-17376.Applicant
• Wiens et al., “Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect,” J Immunol, 2001, 167(4):2179-2186.Applicant
• Wiens et al., “Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion,” J Immunol, 1997, 159(3):1293-1302.Applicant
• Wood et al., “Expression of active human factor VIII from recombinant DNA clones,” Nature, Nov. 22, 1984, 312(5992):330-337.Applicant
• Worn et al., “Stability engineering of antibody single-chain Fv fragments,” J Mol Biol, Feb. 2, 2001, 305(5):989-1010.Applicant
• Written Submissions by Opponent 1 (Alexion Pharmaceuticals, Inc.) in EPO opposition proceedings of EP 2 006 381, dated Apr. 13, 2018, 19 pages.Applicant
• Written Submissions by Opponent 2 (Novo Nordisk A/S) in EPO opposition proceedings of EP 2 006 381, dated Apr. 13, 2018, 14 pages.Applicant
• Written Submissions by Opponent 3 (name Unknown) in EPO opposition proceedings of EP 2 006 381, dated Apr. 13, 2018, 16 pages.Applicant
• Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol, Nov. 19, 1999, 294(1):151-162.Applicant
• Wu et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” J Mol Biol, 2007, 368:652-665.Applicant
• Wu et al., “Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange,” Protein Eng, Dec. 2001, 14(12):1025-1033.Applicant
• Wu et al., “Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization,” J Mol Biol, Jul. 1, 2005, 350(1):126-144.Applicant
• Xiang et al., “Production of Murine V-Human Crl Chimeric Anti-TAG72 Antibody Using V Region cDNA Amplified by PCR,” Mol Immunol, 1990, 27:809-817.Applicant
• Xiang et al., “Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis,” Protein Eng, 2000, 13(5):339-344.Applicant
• Yada et al., “Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations,” J Blood Med, Jul. 2, 2019, 10:171-181.Applicant
• Yamasaki et al., “Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors,” J Pharmacol Exp Ther, 2002, 301:467-477.Applicant
• Yang et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J Mol Biol, Dec. 1995, 254(3):392-403.Applicant
• Yang et al., “Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,” Protein Eng, 2003, 16:761-770.Applicant
• Yarilin, Fundamentals of Immunology, Moscow, Medicina, 1999, p. 171 (with English translation).Applicant
• Yasukawa et al., “Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene,” EMBO J, Oct. 1987, 6(10):2939-2945.Applicant
• Yoneyama et al., “A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A,” Clin Pharmacokinet, Sep. 2018, 57(9):1123-1134. doi: 10.1007/s40262-017-0616-3.Applicant
• Yoneyama et al., “Repeated Time-to-Event Modeling to Characterize the Bleeding-Prophylactic Efficacy of ACE910, a Bispecific Antibody to Factors IXA and X, in Patients with Hemophilia,” Clin Pharmacol Ther, 2016, 99(Suppl 1):S33.Applicant
• Young et al., Efficacy, Safety and Pharmacokinetics (PK) of Once-weekly Prophylactic (Px) Emicizumab (ACE910) in Pediatric (< 12 years) Persons with Hemophilia A with Inhibitors (PwHAwI): Interim Analysis of Single-arm, Multicenter, Open-label, Phase 3 Study (HAVEN 2), Res Pract Thromb Haemost, 2017, 1(Suppl 2):5.Applicant
• Zhu et al., “Remodeling domain interfaces to enhance heterodimer formation,” Protein Sci, Apr. 1997, 6(4):781-788.Applicant
• Zuckier et al., “Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life,” Cancer Res, 1998, 58:3905-3908.Applicant
• Zuo et al., “An efficient route to the production of an IgG-like bispecific antibody,” Protein Eng, 2000, 13(5):361-367.Applicant
• Zwick et al., “The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5,” J Virol, 2004, 78(6):3155-3161.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 13/885,421 dated Jul. 28, 2015, 9 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 11/910,128, dated Nov. 28, 2016, 17 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/093,495, dated May 14, 2021, 130 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 16/093,495, dated Nov. 16, 2021, 39 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/093,495, dated Apr. 11, 2022, 47 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 16/093,495, dated Dec. 14, 2022, 48 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2018/013547, dated Jun. 7, 2018, 6 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2018/013547, dated Oct. 10, 2019, 13 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 16/061,429, dated Jan. 21, 2021, 6 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/061,429, dated Jun. 30, 2021, 54 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 16/330,269, dated Jan. 27, 2021, 7 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/330,269, dated Jun. 9, 2021, 86 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 16/099,341, dated Apr. 17, 2020, 8 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 16/936,575, dated Oct. 6, 2022, 9 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/936,575, dated Feb. 7, 2023, 62 pages.Applicant
• U.S. Appl. No. 10/560,098, filed Nov. 30, 2006, Miyazaki et al.Applicant
• U.S. Appl. No. 10/575,193, filed Oct. 24, 2006, Hattori et al.Applicant
• U.S. Appl. No. 10/575,905, filed Apr. 30, 2007, Hattori et al.Applicant
• U.S. Appl. No. 11/910,128, filed Jan. 21, 2010, Igawa et al.Applicant
• U.S. Appl. No. 11/910,836, filed Jan. 7, 2010, Hattori et al.Applicant
• U.S. Appl. No. 12/295,039, filed Dec. 31, 2009, Igawa et al.Applicant
• U.S. Appl. No. 12/295,075, filed Oct. 22, 2009, Igawa et al.Applicant
• U.S. Appl. No. 12/679,922, fileld Oct. 1, 2010, Igawa et al.Applicant
• U.S. Appl. No. 13/434,643, filed Sep. 20, 2012, Igawa et al.Applicant
• U.S. Appl. No. 13/518,861, filed Oct. 4, 2012, Igawa et al.Applicant
• U.S. Appl. No. 13/522,848, filed Oct. 2, 2012, Igawa et al.Applicant
• U.S. Appl. No. 13/885,421, filed Aug. 30, 2013, Igawa et al.Applicant
• U.S. Appl. No. 14/019,117, filed Dec. 18, 2014, Igawa et al.Applicant
• U.S. Appl. No. 14/019,712, filed Feb. 6, 2014, Igawa et al.Applicant
• U.S. Appl. No. 14/741,786, filed Jun. 17, 2015, Igawa et al.Applicant
• U.S. Appl. No. 15/024,063, filed Mar. 23, 2016, Igawa et al.Applicant
• U.S. Appl. No. 15/132,996, filed Apr. 19, 2016, Igawa et al.Applicant
• U.S. Appl. No. 15/288,965, filed Oct. 7, 2016, Igawa et al.Applicant
• U.S. Appl. No. 15/319,016, filed Dec. 15, 2016, Yoneyama.Applicant
• U.S. Appl. No. 15/402,580, filed Jan. 10, 2017, Hattori et al.Applicant
• U.S. Appl. No. 15/490,936, filed Apr. 19, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/512,094, filed Mar. 17, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/512,187, filed Mar. 17, 2017, Nogami et al.Applicant
• U.S. Appl. No. 15/562,186, filed Sep. 27, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/617,008, filed Jun. 8, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/701,630, filed Sep. 12, 2017, Hattori et al.Applicant
• U.S. Appl. No. 15/725,692, filed Oct. 5, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/782,256, filed Oct. 12, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/875,847, filed Jan. 19, 2018, Igawa et al.Applicant
• U.S. Appl. No. 15/963,345, filed Apr. 26, 2018, Hattori et al.Applicant
• U.S. Appl. No. 16/061,454, filed Jun. 12, 2018, Tanaka et al.Applicant
• U.S. Appl. No. 16/155,673, filed Oct. 9, 2018, Igawa et al.Applicant
• U.S. Appl. No. 16/226,798, filed Dec. 20, 2018, Hattori et al.Applicant
• U.S. Appl. No. 16/318,883, filed Jan. 18, 2019, Igawa et al.Applicant
• U.S. Appl. No. 16/432,790, filed Jun. 5, 2019, Yoneyama.Applicant
• U.S. Appl. No. 16/448,088, filed Jun. 21, 2019, Igawa et al.Applicant
• U.S. Appl. No. 16/459,791, filed Jul. 2, 2019, Igawa et al.Applicant
• U.S. Appl. No. 16/496,089, filed Sep. 20, 2019, Shima et al.Applicant
• U.S. Appl. No. 16/536,385, filed Aug. 9, 2019, Hattori et al.Applicant
• U.S. Appl. No. 18/174,043, filed Feb. 24, 2023, Igawa et al.Applicant
• U.S. Appl. No. 18/176,201, filed Feb. 28, 2023, Igawa et al.Applicant
• U.S. Appl. No. 18/193,697, filed Mar. 31, 2023, Igawa et al.Applicant
• U.S. Appl. No. 18/346,920, filed Jul. 5, 2023, Hattori et al.Applicant
• U.S. Appl. No. 18/466,900, filed Sep. 14, 2023, Yoneyama et al.Applicant
• U.S. Appl. No. 18/479,149, filed Oct. 2, 2023, Yoneyama.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 16/496,089, dated Sep. 1, 2021, 9 pages.Applicant
• Fish & Richardson P.C., Reply to Restriction Requirement in U.S. Appl. No. 16/496,089, filed Oct. 29, 2021, 1 page.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/496,089, dated Dec. 21, 2021, 42 pages.Applicant
• Fish & Richardson P.C., Reply to Office Action of Dec. 21, 2021 in U.S. Appl. No. 16/496,089, filed Jun. 16, 2022, 75 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 16/496,089, dated Aug. 30, 2022, 46 pages.Applicant
• Fish & Richardson P.C., Reply to Action of Aug. 30, 2022 in U.S. Appl. No. 16/496,089, filed Feb. 27, 2023, 22 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/496,089, dated Mar. 28, 2023, 36 pages.Applicant
• U.S. Appl. No. 18/734,272, Yoneyama et al., filed Jun. 5, 2024.Applicant
• U.S. Appl. No. 18/734,434, Yoneyama, filed Jun. 5, 2024.Applicant
• U.S. Appl. No. 18/737,387, Igawa et al., filed Jun. 7, 2024.Applicant
• U.S. Appl. No. 18/748,951, Igawa et al., filed Jun. 20, 2024.Applicant
• U.S. Appl. No. 18/734,272, filed Jun. 5, 20224, Yoneyama et al.Applicant
• U.S. Appl. No. 18/734,434, fileld Jun. 5, 2024, Yoneyama.Applicant
• U.S. Appl. No. 18/737,387, filed Jun. 7, 2024, Igawa et al.Applicant
• U.S. Appl. No. 18/748,951, filed Jun. 20, 2024, Igawa et al.Applicant
• U.S. Appl. No. 18/495,861, Igawa et al., filed Oct. 27, 2023.Applicant
• U.S. Appl. No. 18/505,180, Igawa et al., filed Nov. 9, 2023.Applicant
• U.S. Appl. No. 18/495,861, filed Oct. 27, 2023, Igawa et al.Applicant
• U.S. Appl. No. 18/505,180, filed Nov. 9, 2023, Igawa et al.Applicant
• U.S. Appl. No. 18/425,859, Igawa et al., filed Jan. 29, 2024.Applicant
• U.S. Appl. No. 18/432,567, Igawa et al., filed Feb. 5, 2024.Applicant
• U.S. Appl. No. 18/586,698, Hattori et al., filed Feb. 26, 2024.Applicant
• U.S. Appl. No. 18/425,859, filed Jan. 29, 2024, Igawa et al.Applicant
• U.S. Appl. No. 18/432,567, filed Feb. 5, 2024, Igawa et al.Applicant
• U.S. Appl. No. 18/586,698, filed Feb. 26, 2024, Hattori et al.Applicant
• U.S. Appl. No. 18/883,787, Igawa et al., filed Sep. 12, 2024.Applicant
• U.S. Appl. No. 18/905,228, Hattori et al., filed Oct. 3, 2024.Applicant
• U.S. Appl. No. 18/883,787, filed Sep. 12, 2024, Igawa et al.Applicant
• U.S. Appl. No. 18/905,228, filed Oct. 3, 2024, Hattori et al.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 10/575,193, mailed Mar. 24, 2009, 7 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 10/575,193, mailed Sep. 24, 2009, 22 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 10/575,193, mailed Jun. 23, 2010, 17 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/093,495, dated Aug. 25, 2023, 43 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 16/093,495, dated Oct. 22, 2024, 148 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 16/936,575, dated Nov. 7, 2023, 17 pages.Applicant
• USPTO Office Action in U.S. Appl. No. 16/936,575, dated Sep. 28, 2024, 11 pages.Applicant
• PubChem [online], “Compound Summary for CID 5234, Sodium Chloride,” National Library of Medicine (US), National Center for Biotechnology Information, retrieved on Sep. 23, 2025, at URL <https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-Chloride,> 115 pages.Applicant
• Porello et al.,“OC 03.1—Mim8 Enhances Procoagulant Activity of Select Hemophilia B-causing Factor IX Variants,” Online Presentation at ISTH 2025 Congress Program, Jun. 2, 20251, retrieved on Nov. 1, 20259 from URL <https://s2.goeshow.com/isth/annual/2025/conference_program_sessions.cfm?session_key=E8DF4FED-F837-90B6-65CF-EF2473EDBB50&session_date=Saturday,%20Jun%2021,%202025>, 2 pages.Applicant